For decades, the cannabis industry fought for legitimacy. Patients, clinicians, and advocates worked to move cannabis out of prohibition and into regulated medical programs across much of the United States. That effort is paying off. Patient enrollment continues to grow, research into cannabinoids is accelerating, and policymakers are increasingly willing to acknowledge cannabis as a legitimate therapeutic option. And all of that was happening before President Trump announced his rescheduling executive order.
But just as the industry is gaining credibility, a troubling pattern has emerged. Companies are spending more time and money fighting each other than advancing the industry itself.
RELATED: An industry built by showing up—and why we can’t stop now
Competition is healthy. It drives innovation, improves services, and ultimately benefits patients. But there is a difference between competing on quality, care, and affordability and engaging in disputes that undermine the credibility of the entire sector. When those disputes spill into lawsuits and public accusations, the damage rarely stays confined to the companies involved.
Cannabis businesses still operate under extraordinary scrutiny. Regulators, lawmakers, and healthcare professionals continue to evaluate whether the industry can operate responsibly and whether cannabis deserves a place within the broader healthcare system. Public infighting only reinforces outdated stereotypes that the industry lacks professionalism or maturity.
Those perceptions have real consequences for patients.
In many states, patients still face significant barriers to accessing medical cannabis. Certification costs can be prohibitively high, physicians often lack education on cannabinoid medicine, and lingering stigma continues to discourage some patients from exploring cannabis as a treatment option.
For the millions of Americans managing chronic pain, cancer treatment side effects, neurological disorders, and other serious conditions, cannabis is not a business opportunity or political debate—it is a potential form of care.
RELATED: The patients who built cannabis legalization are being forgotten
That reality should shape the industry’s priorities. I founded Leafwell with the mission to expand access to medical cannabis. Every day we work with patients navigating complicated health challenges and seeking safe, informed guidance about whether cannabis may help them. Their concerns are rarely about which company is competing with which; they are focused on finding responsible care, affordable certification, and clinicians who understand how cannabis may fit into their treatment plan.
Those are the issues the industry should be working together to address.
The cannabis sector has reached a stage where its long-term success depends on trust. Regulators must trust that companies will operate responsibly. Physicians must trust that the industry is grounded in patient care and credible science. And patients must trust that companies are focused on improving health outcomes.
That trust cannot be built through public disputes and legal battles. It is built through professionalism, transparency, and a shared commitment to patient care.
RELATED: DEA opens cannabis registration, but key questions remain
Cannabis companies should absolutely compete with one another, but they should compete on who can best serve patients. Who can lower barriers to certification. Who can improve physician education. Who can expand safe and responsible access to cannabis treatment.
Those are the kinds of competitive dynamics that move an industry forward. The cannabis industry fought too hard for legitimacy to undermine itself now. As the sector continues to mature, the focus must remain on expanding safe, responsible access to medical cannabis for the patients who need it most.